The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A04 | Antiemetics and antinauseants | |
| 3 | A04A | Antiemetics and antinauseants | |
| 4 | A04AD | Other antiemetics | |
| 5 | A04AD12 | Aprepitant |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 95 mg |
| PAREN - Parenteral | 95 mg |
| Active Ingredient | Description | |
|---|---|---|
| Aprepitant |
Aprepitant is a selective high-affinity antagonist at human substance P neurokinin 1 (NK1) receptors. |
|
| Fosaprepitant |
Fosaprepitant is the prodrug of aprepitant and when administered intravenously is converted rapidly to aprepitant. The contribution of fosaprepitant to the overall antiemetic effect has not fully been characterised, but a transient contribution during the initial phase cannot be ruled out. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| EMEND Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
| EMEND IV Fosaprepitant for injection | Health Products and Food Branch (CA) | MPI, CA: SPM | |
| IVEMEND Powder for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
